Patent SG-11201804265X-A (SG)
Title: Antibodies and methods of use thereof
Inventor: WILSON NICHOLAS S
IPC: C07K16/30
Filed: 2016-12-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ires.. 00) (43) International Publication Date ..... ..sr ,„,„.1 8 June 2017 (08.06.2017) WI P0 I P CT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/096179 Publication Al Number (51) International Patent Classification: St. #27B, New York, New York 10017 (US). MERG- A61K 39/395 (2006.01) C07K 16/28 (2006.01) HOUB, Taha; 10 Huron Ave., Apt. 14K, Jersey City, New A61K 47/68 (2017.01) C07K 16/30 (2006.01) Jersey 07306 (US). BREOUS-NYSTROM, Ekaterina V.; (21) International Application Number: Waldenburgerstrasse 15, 4052 Basel (CH). SEIBERT, Volker; Tumringer Str. 261c, 79539 Lorrach (DE). TSUJI, PCT/US2016/064642 Takemasa; 249 Palmdale Drive, Apt. 5, Williamsville, (22) International Filing Date: New York 14221 (US). LEGER, Olivier; 603 Route des 2 December 2016 (02.12.2016) Luches, 74800 Saint-Sixt (FR). UNDERWOOD, Dennis J.; 28 John A Andrew St., Jamaica Plain, Massachusetts (25) Filing Language: English 02130 (US). VAN DIJK, Marc; Gaailaan 16, 3722ZH (26) Publication Language: English Bilthoven (NL). (30) Priority Data: (74) Agents: STEFFE, Eric K. et al.; Sterne, Kessler, Gold- 62/262,369 2 December 2015 (02.12.2015) US stein & Fox P.L.L.C., 1100 New York Avenue, NW, 62/419,911 9 November 2016 (09.11.2016) US Washington, District of Columbia 20005 (US). (71) Applicants: AGENUS INC. [US/US]; 3 Forbes Road, (81) Designated States (unless otherwise indicated, for every Lexington, Massachusetts 02421 (US). MEMORIAL kind of national protection available): AE, AG, AL, AM, SLOAN-KETTERING CANCER CENTER [US/US]; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 1275 York Avenue, New York, New York 10065 (US). BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, LUDWIG INSTITUTE FOR CANCER RESEARCH DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, LTD. [CH/CH]; Stadelhoferstrasse 22, 8001 Zurich (CH). HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (72) Inventors: WILSON, Nicholas S.; 68 Electric Avenue, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Apt. 1, Somerville, Massachusetts 02144 WAIGHT, (US). OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Jeremy D.; 25 Charlton Street, Apt. 403, Everett, Mas- SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, sachusetts 02149 (US). RITTER, Gerd; Ludwig Institute TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, for Cancer Research, 666 Third Avenue, 28th Fl., New ZW. York, New York 10017 SCHAER, David; 715 (US). Shore Acres Drive, Mamaroneck, New York 10543 (US). (84) Designated States (unless otherwise indicated, for every HIRSCHHORN-CYMERMAN, Daniel; 255 East 49th kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [Continued on next page] (54) Title: ANTIBODIES AND METHODS OF USE THEREOF Figure 2A activated Hut102 cells Binding to (GITR+/0X40+) 1750- 1500- -N- DuoBody pab1876 X pab2049 1250- -A- pab1876 4- pab2049 — r a -& DuoBody pab1876 X isotype 1000- L T )1 -e- DuoBody pab2049 X isotype 750- A 0 -0- Isotype control 500- * 0 A 250- 1-1 r _ Mr .4t 0 -4 -3 -2 -1 0 1 2 01 N Antibody nM [log] 1-1 01 lab , (57) : The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR - *C and/or human 0X40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specific - to human GITR and 0X40 and modulate GITR and/or 0X40 activity, enhance, activate, or induce GITR and/or 0X40 1 . 1 N ally bind e.g. , activity, or reduce, deactivate, or inhibit GITR and/or 0X40 activity. The present disclosure also provides methods for treating dis - Q ei orders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or 0X40 and modulates 0 GITR and/or 0X40 activity, e.g., enhances, activates, or induces GITR and/or 0X40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or 0X40 and modulates GITR and/or 0X40 activity, e.g., reduces, deactivates, or inhibits GITR and/or 0X40 activity. WO 2017/096179 Al IMEDIMOMMIONMEHME1011111111111111101111111111111111111 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Published: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, DE, LT, SE, GA, — with — with international search sequence listing part report (Art. 21(3)) of description (Rule 5.2(a)) GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).